Inactive Instrument

C4X Discovery Holdings plc

Equities

C4XD

GB00BQQ2RV18

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 16:46:00 25/04/2024 BST			5-day change	1st Jan Change
12 ^GBX	+27.32%		-.--%	+33.33%

04-25	Norcros sells Johnson Tiles UK; Trifast trading well	AN
04-25	C4X Discovery Set for Friday Delisting from London Bourse's AIM	MT

C4X Discovery : focused and funded after £15.95mln strategic divestment

August 03, 2023 at 08:12 am

August 3, 2023News

C4X Discovery focused and funded after £15.95mln strategic divestment

Bhavna Hunjan CBO and Nick Ray CSO talk to Proactive Investor on the Indivior acquisition of its Orexin-1 programme.

Watch Video

Attachments

Original Link
Original Document
Permalink

Disclaimer

C4X Discovery Holdings plc published this content on 03 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 August 2023 07:11:20 UTC.

Latest news about C4X Discovery Holdings plc

Norcros sells Johnson Tiles UK; Trifast trading well	04-25	AN
C4X Discovery Set for Friday Delisting from London Bourse's AIM	04-25	MT
C4X Discovery shareholders approve of taking firm private	04-15	AN
C4X Discovery seeks AIM delisting but half-year revenue skyrockets	03-27	AN
C4X Discovery Seeks to Delist From London's AIM Amid Financial Markets Downturn	03-27	MT
Earnings Flash (C4XD.L) C4X DISCOVERY HOLDINGS Posts Fiscal H1 Revenue GBP24.6M	03-27	MT
Earnings Flash (C4XD.L) C4X DISCOVERY HOLDINGS Reports Fiscal H1 EPS GBX7.06	03-27	MT
C4X Discovery Holdings plc Reports Earnings Results for the Half Year Ended January 31, 2024	03-27	CI
C4X Discovery Holdings plc Announces Stepping Down of Mario Polywka as Non-Executive Director	01-18	CI
Stocks down ahead of US Fed minutes	01-03	AN
Stocks down before Fed minutes and US PMI data	01-03	AN
AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals	01-03	AN
Stocks mixed pre-Fed minutes, amid Asia losses	01-03	AN
C4X receives USD11 million from AstraZeneca following NRF2 trials	01-03	AN
Stocks to open flat pre-Fed minutes, jobs data	01-03	AN
C4X Discovery Shares Rise on AstraZeneca Milestone Payment	01-03	DJ
C4X Discovery Receives $11 Million Milestone Payment from AstraZeneca	01-03	MT
C4X Discovery Holdings plc Receives Milestone Payment of $11 Million from AstraZeneca	01-03	CI
C4X Discovery shares topple 10% as loss widens on higher costs	12-14	AN
Earnings Flash (C4XD.L) C4X DISCOVERY HOLDINGS Posts FY23 Revenue GBP1.7M	12-14	MT
Earnings Flash (C4XD.L) C4X DISCOVERY HOLDINGS Reports FY23 Loss GBX-4.42	12-14	MT
C4X Discovery Holdings plc Reports Earnings Results for the Full Year Ended July 31, 2023	12-14	CI
Transcript : C4X Discovery Holdings plc, 2023 Earnings Call, Dec 14, 2023	12-14
C4X Discovery inks Indivior deal, Digitalbox expands	01/08/23	AN
FTSE 100 Index Down 0.4% at Close, Dragged by Miners, Oil Stocks	01/08/23	DJ

Chart C4X Discovery Holdings plc

Duration

Period

More charts

Company Profile

C4X Discovery Holdings plc is a drug discovery company. The Company has a portfolio ranging from early-stage target opportunities to late-stage drug discovery programs. The Company has three commercially partnered programs with one candidate in clinical development. Its portfolio focuses on treatments for immuno-inflammatory diseases. The Companyâs pipeline products include MALT-1 Inhibitor, a4B7 Integrin Inhibitor, IL-17A Inhibitor, NRF-2 Activator, and others. Its target identification platform (Taxonomy3) is used to analyze complex genetic datasets to identify and characterize drug target candidates. Taxonomy3 offers the potential for patient stratification in clinical trials, ensuring patient targeting and the potential for rescuing failed clinical trials or for drug repurposing. PatientSeek is its new platform that applies the mathematical approach of Taxonomy3 to stratify patients for treatments based on their genetics.

Sector

Biotechnology & Medical Research

Calendar

11/12/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+64.92%	62.86B
IQVIA HOLDINGS INC.	-1.85%	41.38B
LONZA GROUP AG	+45.89%	40.38B
CELLTRION, INC.	-8.93%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	18.9B
BIO-TECHNE CORPORATION	+4.21%	12.67B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.27B
MEDPACE HOLDINGS, INC.	+27.42%	12.07B

Other Biotechnology & Medical Research